Benelux biotech strength hampered by fragmented investment, experts discuss path to unified corridor

In a recent episode of BioSpace's "Denatured" podcast, host Jennifer C. Smith-Parker talks with Christina Takke of V-Bio Ventures and Mariette van der Velden‑Roesink of Curie Capital about the biotech landscape in the Benelux region.

The guests highlight that Belgium, the Netherlands and Luxembourg continue to produce world‑class scientific research, but the flow of capital remains uneven and scattered across the three countries.

They argue that creating a more coordinated investment corridor will require greater collaboration among venture firms, policymakers and academic institutions, as well as clearer cross‑border funding mechanisms.

The discussion underscores both the promise of the region’s talent pool and the challenges of aligning investors to unlock that potential.